Related Experiment Video
Updated: Jul 6, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Washed microbiota transplantation alleviates tyrosine kinase inhibitors associated gastrointestinal adverse effects
Weihong Wang1,2, Xinyi He1,2, Chenchen Liang1,2
1Department of Microbiota Medicine & Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Abstract:
Gut microbiota dysbiosis is implicated in tyrosine kinase inhibitor (TKI)-induced gastrointestinal adverse effects (GAEs), often necessitating medication adjustments or discontinuation in severe or persistent cases. This study aimed to evaluate the efficacy and safety of washed microbiota transplantation (WMT) in managing TKI-induced GAEs. This prospective study involved cancer patients presenting TKI-induced GAEs. The primary outcome was the clinical remission rate at Week 8 post-WMT, which was assessed by the common terminology criteria for adverse events grade. The secondary outcomes included the clinical asymptomatic rate, the onset time of clinical remission, and the variation of C-reactive protein (CRP) levels. Twenty-four patients undergoing 66 WMTs were analyzed. The overall clinical remission and asymptomatic rates were 75.00% (18/24) and 29.17% (7/24), respectively. GAEs, including diarrhea, abdominal pain, and abdominal distention, showed significant improvement post-WMT (all p < .05), while hematochezia exhibited a decreasing trend in severity. Median time to remission was 14.5 days (inter-quartile range, 7-24). Within 8 weeks post-WMT, three initially responsive patients experienced relapse. CRP levels significantly decreased (p < .05), and no severe adverse events were reported. This study proposes WMT as a potential treatment for TKI-induced GAEs, particularly for patients who do not respond adequately to conventional treatments.
Insights
Washed microbiota transplantation (WMT) effectively treats tyrosine kinase inhibitor-induced gastrointestinal issues in cancer patients. This gut health therapy shows promise for managing side effects when standard treatments fall short.
Area of Science:
- Gastroenterology
- Oncology
- Microbiology
Background:
- Gut microbiota dysbiosis is linked to tyrosine kinase inhibitor (TKI)-induced gastrointestinal adverse effects (GAEs).
- GAEs can lead to dose adjustments or treatment cessation, impacting cancer therapy efficacy.
- Current management strategies for TKI-induced GAEs may be insufficient for some patients.
Purpose of the Study:
- To assess the efficacy and safety of washed microbiota transplantation (WMT) for managing TKI-induced GAEs.
- To determine clinical remission and asymptomatic rates following WMT.
- To evaluate changes in C-reactive protein (CRP) levels as a marker of inflammation.
Main Methods:
- A prospective study involving cancer patients experiencing TKI-induced GAEs.
- Patients received washed microbiota transplantation (WMT).
- Outcomes measured included clinical remission, asymptomatic status, time to remission, and CRP levels using standard grading criteria.
Main Results:
- A 75% clinical remission rate was observed at 8 weeks post-WMT.
- Significant improvements were noted in diarrhea, abdominal pain, and distention (p < .05).
- C-reactive protein levels decreased significantly, and no severe adverse events were reported.
Conclusions:
- Washed microbiota transplantation (WMT) is a safe and effective option for TKI-induced GAEs.
- WMT offers a potential therapeutic avenue for patients unresponsive to conventional treatments.
- Further research may explore WMT's role in maintaining long-term remission and preventing GAE relapse.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Microbiota Modulation by Antibiotics

